Exchange: NASDAQ·Updated 08:00 AM EST

AVDL Avadel Pharm Sp ADR

$21.64
$0.314
(1.45%)
Pre-Market
Prev Close $21.64
Reported EarningsNov 4
Mkt Cap$2.11B
Vol200.00

About AVDL

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
53

Neutral Sentiment

How do you feel about AVDL?

Advertisement|Remove ads.